Topic: drug prices


New Drug Pricing Strategies for a Changing Global Market

During this webinar, PwC’s Health Research Institute will review findings from a new global survey of industry executives, and provide analysis and commentary on key drug pricing issues.

The top 10 pharma R&D budgets in 2016

Last year, biopharma won its share of new drug approvals as R&D spending came to fruition, but drugmakers also suffered a number of setbacks, cut research staff, rejigged their operations and refocused their pipelines.


7. Sanofi

Sanofi had a bit of a year to forget when it came to buying up biotechs and expanding its pipeline—it failed to beat out Pfizer in its winning $14 billion bid for cancer biotech Medivation, losing out on some increasingly hot cancer candidates and blockbuster prostate cancer med Xtandi.